Home › Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments
 

Keywords :   


Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments

2014-03-05 05:29:31| drugdiscoveryonline News Articles

Eisai Co., Ltd. and Biogen Idec recently announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401

Tags: enter develop disease collaboration

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
05.07Simplestream reveals preferred technology partnership with Freely
More »